A Delaware federal court officially ended UroGen Pharma Ltd.'s patent infringement suit against Teva Pharmaceuticals Inc. pursuant to the parties’ stipulation of dismissal. The US District Court for ...

The next phase of Andrew Dudum’s quest to change how Americans get their health care is taking shape behind the walls of a nondescript factory, tucked off a side street in Silicon Valley. As ...

Hims & Hers announced it will offer generic semaglutide through its direct-to-consumer virtual care platform to eligible customers in Canada, following Novo Nordisk's loss of Canadian patent ...

May 21 (Reuters) - Hims & Hers Health (HIMS.N), opens new tab said on Thursday it is now offering Canadians a generic version of semaglutide, the active ingredient in Novo Nordisk's (NOVOb.CO), opens ...

Proceeds intended to be used to preserve financial flexibility as Hims & Hers executes on its international expansion strategy, including the proposed acquisition of Eucalyptus, invests in technology ...

While Hims management raised its revenue outlook for the year, it significantly lowered its adjusted EBITDA guidance. It now expects revenue to range from $2.8 billion to $3 billion, with adjusted ...

JPMorgan cut Hims & Hers Health’s (HIMS) price target to $33 from $35 on margin pressure from its shift away from higher-margin compounded to branded GLP-1 medications. Act now: the analyst who called ...

Sales grew only 4% in the quarter, despite subscriber growth of 9%. (Which is to say, this may be a story of more consumers spending less money at Hims & Hers.) Accentuating the positive, though, CEO ...

Online health and wellness company Hims & Hers posted a $92 million loss in the first quarter as it shifts its business from selling compounded weight loss drugs to branded GLP-1 medications. During ...

Digital health firm Hims & Hers' stock plummeted on Tuesday on weak first-quarter earnings. Hims reported a net loss of $92 million in the first quarter, up from $50 million last year. The company ...